Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen

European Journal of Cancer

Volumn 39, Issue 4, 2003, Pages 462-468

  Miller, W R ^a   Dixon, J M ^b   Macfarlane, L ^b   Cameron, D ^a   Anderson, T J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Histopathology; Letrozole; Neoadjuvant; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS RATE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 0345314101     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00600-7     Document Type: Article

References (30)

1. Forrest A.P., Levack P.A., Chetty U.et al. A human tumour model. Lancet. 2:1986;840-842.
2. Bonadonna G., Veronesi U., Brambilla C.et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82:1990;1539-1545.
3. Powles T.J., Hickish T.F., Makris A.et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J. Clin. Oncol. 13:1995;547-552.
4. Cameron D.A., Anderson E.D., Levack P.et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br. J. Cancer. 76:1997;1099-1105.
5. Keen J.C., Dixon J.M., Miller E.P.et al. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res. Treat. 44:1997;123-133.
6. Miller W.R., Anderson T.J., Hawkins R.A.et al. Neoadjuvant endocrine treatment. the Edinburgh experience Howell A., Dowsett M. Primary Medical Therapy for Breast Cancer. ESO Scientific Updates, vol. 4. 1999;1-11 Elsevier Science BV, Amsterdam.
7. Bonneterre J., Thürlimann B., Robertson J.F.R.et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women. results of the tamoxifen or Arimidex randomized group efficacy and tolerability study J. Clin. Oncol. 18:2000;3748-3757.
8. Mouridsen H., Gershanovich M., Sun Y.et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. results of a phase III study of the International Letrozole Breast Cancer Group J. Clin. Oncol. 19:2001;2596-2606.
9. Ellis M.J., Coop A., Singh B.et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer. evidence from a phase II randomized trial J. Clin. Oncol. 19:2001;3808-3816.
10. Forouhi P., Dixon J.M., Leonard R.C., Chetty U. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br. J. Surg. 82:1995;79-82.
11. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. experience from a large study with long-term follow-up Histopathology. 19:1991;403-410.
12. Gerdes J., Becker M.H., Key G., Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J. Pathol. 168:1992;85-86.
13. Lebat-Moleur F., Guillermet C., Lorimier P., Robert C., Lanteujoul S. TUNEL apoptotic cell detection in tissue sections. critical evaluation and improvement J. Histochem. Cytochem. 46:1998;327-334.
14. Simpson J.F., Dutt P.L., Page D.L. Expression of mitoses per thousand cells and cell density in breast carcinomas. a proposal Hum. Pathol. 23:1992;608-611.
15. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11:1998;155-168.
16. Demers L.M., Lipton A., Harvey H.A.et al. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced breast cancer. J. Steroid. Biochem. Mol. Biol. 44:1993;687-691.
17. Miller W.R., Telford J., Smith H., Dixon J.M. Effect of neoadjuvant treatment with the aromatase inhibitor letrozole on peripheral synthesis of oestrogen, uptake by the breast and in situ production of oestrogen within mammary tissues. Breast Cancer Res. Treat. 50:1998;228.
18. Cameron D.A., Keen J.C., Dixon J.M.et al. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur. J. Cancer. 36:2000;845-851.
19. Cameron D.A., Ritchie A.A., Miller W.R. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. Eur. J. Cancer. 37:2001;1545-1553.
20. Sasano H., Sato S., Ito K.et al. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr. Relat. Cancer. 6:1999;197-204.
21. Miller W.R., Dixon J.M., Cameron D.A., Anderson T.J. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J. Steroid Biochem. Mol. Biol. 79:2001;103-107.
22. Makris A., Powles T.J., Allred D.C., Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen-treated breast cancer patients and the relationship with response. Breast Cancer Res. Treat. 48:1998;11-20.
23. Chang J., Powles T.J., Allred D.C.et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin. Cancer Res. 6:2000;616-621.
24. Johnstone R.D., Smith I.E., Dowsett M. Place of aromatase inhibitors in the endocrine therapy of breast cancer. Miller W.R., Santen R.J. Aromatase Inhibition and Breast Cancer. 2001;29-50 Marcel Dekker, New York.
25. Anderson T.J., Dixon J.M., Miller W.R. Is phenotypic drift in breast cancer disclosed in neoadjuvant endocrine therapy? Breast Cancer Res. Treat. 57:1999;137.
26. Kenny F.S., Willisher P.C., Gee J.M.et al. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res. Treat. 65:2001;135-144.
27. Katzenellenbogen B.S., Choi I., Delage-Mourroux R.et al. Molecular mechanisms of estrogen action. selective ligands and receptor pharmacology J. Steroid Biochem. Mol. Biol. 74:2000;279-285.
28. MacGregor J.I., Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 50:1998;151-196.
29. Hu X.F., Veroni M., De Luise M.et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer. 55:1993;873-876.
30. Bajetta E., Zilembo N., Dowsett M.et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur. J. Cancer. 35:1999;208-213.